| SYM | Name |
|---|---|
 | SPAC/IPO |
 | LOI |
 | Vereinbarung |
 | Wahl |
 | Fusion |
 | IPO |
 | Abwicklung |
Filterable News List
Find relevant news faster.
Explore news on SPACs, IPOs, mergers, and publicly traded companies. Filter by company, industry, or topic to find relevant developments, deals, and market activity faster.
News List
| details_shortcode_en | Year | Month | Status | Industry | Category | Rating | sec_cik_company | sec_cik_spac | name_company | name_spac | ticker_company | ticker_spac | ticker_stockdio | ticker_spac_stockdio | ticker_tradingview | title | title_seo | description_seo | uu_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8/1028 min ago newcleo Completes Business Combination and Begins Trading on Nasdaq
Nuclear Power
Merger / DESPAC
Merger:
Sep 22, 2026  Industry: FABRICATED PLATE WORK (BOILER SHOPS) Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 23, 2026 6:28 AM ET newcleo Completes Business Combination and Begins Trading on NasdaqParis, France, and New York, NY, September 21, 2026 - newcleo plc, a pioneer in advanced modular reactor technology and nuclear fuel manufacturing, announced the completion of its business combination with NewHold Investment Corp III, a publicly listed special purpose acquisition company. The transaction establishes a strong capital foundation for newcleo as a public company,… … Read on — Pro Members About newcleo plc: newcleo is an innovative nuclear energy company developing AMRs cooled by liquid lead, and nuclear fuel from recycled nuclear waste, with the goal of delivering abundant, competitive, low-carbon energy. The Company was founded by physicist-entrepreneur Stefano Buono following the USD 3.9 billion sale of his previous venture – Nasdaq-listed nuclear medicine company Advanced Accelerator Applications – to Novartis. With over $80 million in revenue, other income, and financial income in 2024 including from its operating companies, approximately $780 million in private funding, and more than 900 highly skilled employees across Europe and the 6 United States, the Company has built a network of over 100 industry partnerships and supports its growth through the targeted acquisition and vertical integration of key companies in the nuclear supply chain. Visit www.newcleo.com. | 2026 | 09 / September | | Nuclear Power | Merger / DESPAC | 8 | 2.131.813 | 2.043.699 | newcleo plc | NewHold Investment Corp. III | NWCL | NHIC | NWCL | NHIC | NWCL | newcleo Completes Business Combination and Begins Trading on Nasdaq | newcleo Completes SPAC Business Combination and Nasdaq Listing | newcleo completes its business combination with NewHold Investment Corp III, raising $247 million in gross proceeds to trade on Nasdaq under ticker NWCL. | 8b68d0c8-b738-11f1-aa56-277af14ba041 |
7/10Freeyesterday Haymaker Acquisition Corp V Completes $287.5 Million Initial Public Offering
SPAC
Initial Public Offering / IPO SPAC
IPO / SPAC:
Sep 17, 2026  Industry: BLANK CHECKS Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 22, 2026 5:19 PM ET Haymaker Acquisition Corp V Completes $287.5 Million Initial Public OfferingNew York, NY, USA - Haymaker Acquisition Corp V announced the closing of its initial public offering of 28,750,000 units at a price of $10.00 per unit, generating gross proceeds of $287,500,000. The offering includes 3,750,000 units issued pursuant to the full exercise of the underwriters' over-allotment option. The company's units began trading on the New York Stock Exchange under the ticker symbol HYACU. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with whole warrants allowing the purchase of one Class A ordinary share at $11.50 per share. Once separated, the Class A ordinary shares and warrants are expected to trade under the symbols HYAC and HYACW, respectively. Transaction Details
The proceeds from the initial public offering and a simultaneous private placement of warrants were placed in trust. Haymaker Acquisition Corp V is a blank check company formed to execute a business combination with one or more businesses, focusing primarily on companies in the industrial, consumer, and consumer-related products and services industries. Cantor Fitzgerald & Co. and William Blair acted as joint book-running managers for the offering, while Roth Capital Partners served as co-manager. About Haymaker Acquisition Corp V: Haymaker Acquisition Corp V is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We may pursue an initial business combination in any business or industry. | 2026 | 09 / September | | SPAC | Initial Public Offering / IPO SPAC | 7 | 2.111.838 | Haymaker Acquisition Corp V | HYAC | HYAC | HYAC | Haymaker Acquisition Corp V Completes $287.5 Million Initial Public Offering | Haymaker Acquisition Corp V Completes $287.5M IPO | Haymaker Acquisition Corp V completes its $287.5 million initial public offering on the NYSE under the ticker symbol HYACU. | 2f56a62b-b6ca-11f1-aa56-277af14ba041 | ||||
7/10Freeyesterday TriSalus Life Sciences Receives FDA Clearance for TriNav Advance
Biotechnology
Business Update
Merger:
Aug 11, 2023 Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS Market Cap.: 314.01 m. Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 22, 2026 4:36 PM ET TriSalus Life Sciences Receives FDA Clearance for TriNav AdvanceWESTMINSTER, Colo. - September 22, 2026 - TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio. TriNav Advance expands the company's portfolio of PEDD devices by adding access to small, distal vessels via a compatible delivery microcatheter while preserving enhanced therapeutic delivery and off-target protection. Interventional radiologists can now pair the device with a compatible microcatheter of their choice, providing greater flexibility across a broader range of procedures and anatomies.
Key Highlights About TriSalus Life Sciences, Inc.: TriSalus Life Sciences® is an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy. The Company’s platform features FDA-cleared devices and a clinical-stage investigational immunotherapeutic, all designed to enhance treatment efficacy. Its proprietary Pressure-Enabled Drug Delivery™ (PEDD) technology optimizes therapeutic delivery to tumors while minimizing off-target exposure. TriSalus’ FDA-cleared devices include the TriNav® Infusion System, designed for hepatic arterial infusion to treat liver tumors and the Pancreatic Retrograde Venous Infusion System, specifically developed to address the unique challenges of drug delivery in pancreatic tumors. The PEDD approach overcomes anatomic barriers by modulating pressure and flow, improving therapeutic delivery directly to the tumor and reducing delivery of toxic therapeutics to healthy tissues—offering the potential to significantly enhance patient outcomes and reduce complications. Additionally, the Company’s investigational immunotherapeutic, nelitolimod, is designed to counteract the immunosuppressive environment created by many tumors, which often renders conventional treatments less effective. Data from Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials suggest that nelitolimod delivered via PEDD technology produces promising immune-modulating effects both within the liver and systemically. Nelitolimod targets TLR9, a receptor expressed across various cancer types, and its delivery leverages PEDD technology to address physical barriers that impede treatment in solid tumors.
In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on Twitter and LinkedIn. | 2026 | 09 / September | | Biotechnology | Business Update | 7 | 1.826.667 | 1.826.667 | TriSalus Life Sciences, Inc. | MedTech Acquisition Corp. | TLSI | MTAC | TLSI | MTAC | TLSI | TriSalus Life Sciences Receives FDA Clearance for TriNav Advance | TriSalus Receives FDA Clearance for TriNav Advance | TriSalus Life Sciences announced FDA 510(k) clearance for TriNav Advance, expanding its Pressure-Enabled Drug Delivery portfolio for liver embolization. | 2bd8b55e-b6c3-11f1-aa56-277af14ba041 |
6/10Freeyesterday Palmer Square Capital BDC Declares Third Quarter 2026 Supplemental Dividend
Financial Services
Dividend
IPO:
Jan 18, 2024  Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 22, 2026 4:23 PM ET Palmer Square Capital BDC Declares Third Quarter 2026 Supplemental DividendMISSION WOODS, Kansas, September 22, 2026 -- Palmer Square Capital BDC Inc. (NYSE: PSBD), an externally managed business development company, announced that its Board of Directors has declared a third quarter 2026 supplemental dividend of $0.02 per share. Shareholders of record as of September 25, 2026, will receive the supplemental dividend, which is payable on October 13, 2026. Transaction Details
The supplemental dividend will be funded from the excess of the company's quarterly undistributed net investment income above the third quarter 2026 base dividend. About Palmer Square: Palmer Square Capital BDC Inc. (NYSE: PSBD) is an externally managed, non-diversified closed-end management investment company that primarily lends to and invests in corporate debt loans, including but not limited to large private U.S. companies in the broadly syndicated loan market, as well as the direct large cap private credit market. PSBD has elected to be regulated as a business development company under the Investment Company Act of 1940. PSBD’s investment objective is to maximize total return, comprised of current income and capital appreciation. PSBD’s current investment focus is guided by two strategies that facilitate its investment opportunities and core competencies: (1) investing in corporate debt loans and, to a lesser extent, (2) investing in other debt securities which may include collateralized loan obligation debt and equity. PSBD’s investment activities are managed by its investment adviser, Palmer Square BDC Advisor LLC, an affiliate of Palmer Square Capital Management LLC. | 2026 | 09 / September | | Financial Services | Dividend | 6 | 1.794.776 | Palmer Square | PSBD | PSBD | PSBD | Palmer Square Capital BDC Declares Third Quarter 2026 Supplemental Dividend | Palmer Square Capital BDC Announces Supplemental Dividend | Palmer Square Capital BDC Inc. declares a Q3 2026 supplemental dividend of $0.02 per share. View key dates and payment details. | 2ab718da-b6c3-11f1-aa56-277af14ba041 | ||||
5/10yesterday Vogenx Appoints Ken Toombs to Board of Directors
Biotechnology
Change of Management
IPO:
Aug 12, 2026 Industry: PHARMACEUTICAL PREPARATIONS Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 22, 2026 4:13 PM ET Vogenx Appoints Ken Toombs to Board of DirectorsRaleigh, North Carolina, USA - Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage developer of novel therapeutics for serious metabolic and gastrointestinal diseases, announced the appointment of Ken Toombs to its Board of Directors, effective September 21, 2026. Mr. Toombs will serve as an independent director and as Chair of the Audit Committee.Mr. Toombs brings three decades… … Read on — Pro Members About Vogenx, Inc.: We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, and towards regulatory approval.
Our lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome, or GDCS. Mizagliflozin is a selective inhibitor of SGLT1, a glucose transporter present in the gastrointestinal tract responsible for transporting dietary glucose into the bloodstream. | 2026 | 09 / September | | Biotechnology | Change of Management | 5 | 1.903.784 | Vogenx, Inc. | VOGX | VOGX | VOGX | Vogenx Appoints Ken Toombs to Board of Directors | Vogenx Appoints Ken Toombs to Board of Directors | Vogenx appoints former PA Consulting CEO Ken Toombs as an independent director and Audit Committee Chair to support scaling operations. | b3c349b5-b6c1-11f1-aa56-277af14ba041 | ||||
7/10yesterday Ticketplus Expands Its Own Brand into Argentina with the Acquisition of Autoentrada
Entertainment
Acquisition
IPO:
Aug 07, 2026 Industry: MISCELLANEOUS AMUSEMENT & RECREATION Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 22, 2026 8:43 AM ET Ticketplus Expands Its Own Brand into Argentina with the Acquisition of AutoentradaSantiago, Chile and Cordoba, Argentina - September 21, 2026 - Ticketplus Ltd. (NYSE American: TP) announced today that it has acquired Autoentrada S.A., an Argentine ticketing company based in Cordoba with over two decades of operating history. This marks Ticketplus's first acquisition since its August 2026 initial public offering, expanding the company's own brand into… … Read on — Pro Members About Ticketplus Ltd.: We are a technology company focused on powering the live entertainment industry across Latin America. We provide a proprietary, full-stack event platform that supports event discovery, primary ticketing, access control, payments, analytics, and post-event insights for promoters, venues, sports organizations, and ticketing companies. Since our founding in 2014 in Chile, we have expanded through a dual business model strategy: (1) a full-operations model in Chile, our home market, where we act as the primary ticketing platform and deliver end-to-end infrastructure and services and (2) a white-label software-as-a-service, or SaaS, model where we license our platform to regional ticketing companies, venues, and promoters who operate under their own brands while using our technology. Our platform is designed to increase attendance and maximize revenue for our clients by combining reliable transaction processing with data-driven pricing, personalization, and conversion-optimized experiences. | 2026 | 09 / September | | Entertainment | Acquisition | 7 | 2.104.296 | Ticketplus Ltd. | TP | TP | TP | Ticketplus Expands Its Own Brand into Argentina with the Acquisition of Autoentrada | Ticketplus Acquires Autoentrada to Expand in Argentina | Ticketplus acquires Argentine ticketing company Autoentrada in its first post-IPO deal, expanding its brand presence and direct operations into Argentina. | de0c62ef-b682-11f1-aa56-277af14ba041 | ||||
7/10yesterday IMC Rare Earths Reports 73% In-Situ Rare Earth Recovery at Itarantim Project
Raw Materials
Business Update
IPO:
Jul 29, 2026 Industry: METAL MINING Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 22, 2026 8:30 AM ET IMC Rare Earths Reports 73% In-Situ Rare Earth Recovery at Itarantim ProjectSAO PAULO, BRAZIL - September 22, 2026 - IMC Rare Earths Ltd (NYSE American: IMC) announced encouraging metallurgical testwork results from the University of Brighton showing that a high proportion of rare earths can be recovered from its Itarantim Project in Brazil. The findings support further evaluation of in-situ recovery (ISR) as a potentially simpler,… … Read on — Pro Members About IMC Rare Earths Ltd: We are a mineral exploration and development company, and our main rare earth element (or “REE”) project is the Itarantim Project located in the States of Bahia and Minas Gerais, Brazil. Drilling on this ionic adsorbed clay (“IAC”) REE deposit has identified a mineral resource of 1.1 billion MT with an average grade of 1,233 ppm total rare earth oxides (“TREO”). We have no operating revenues and do not anticipate generating revenues for the foreseeable future. We were incorporated on September 19, 2025 in the Cayman Islands as IMC Rare Earths Ltd.
We are developing rare earth mining projects in Brazil with a focus on exploration, development and long-term supply of certain REEs. We are seeking to establish one of the largest high-grade magnet rare earth element (or “MREE”) deposits outside of China and Myanmar, with the ability to supply to rare earth metal markets in the United States and Europe. Based on our exploration results to date, we believe we have the potential to integrate the Itarantim Project into an emerging U.S. rare earth supply chain by supplying our target markets’ growing demand for MREOs. | 2026 | 09 / September | | Raw Materials | Business Update | 7 | 2.098.395 | IMC Rare Earths Ltd | IMC | IMC | IMC | IMC Rare Earths Reports 73% In-Situ Rare Earth Recovery at Itarantim Project | IMC Rare Earths Reports 73% In-Situ Recovery at Itarantim | IMC Rare Earths announces positive metallurgical testwork from the University of Brighton showing 73% rare earth recovery at the Itarantim Project. | 79458e57-b681-11f1-aa56-277af14ba041 | ||||
5/10FreeSep 21, 2026 Hycroft Provides Project Update and Unveils Refreshed Brand Identity
Raw Materials
Business Update
Merger:
Jun 01, 2020 Industry: GOLD AND SILVER ORES Market Cap.: 1.93 bn. Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 21, 2026 5:30 PM ET Hycroft Provides Project Update and Unveils Refreshed Brand IdentityWinnemucca, Nevada, USA - Hycroft Mining Holding Corporation (Nasdaq: HYMC), a US-based gold and silver exploration and development company, provided an update on its technical initiatives and introduced a refreshed brand identity to reflect its ongoing transformation. The company is evaluating multiple pathways to unlock shareholder value, supported by an experienced leadership team and Board of Directors. As part of its modernization, Hycroft launched an updated corporate website. Key Highlights
About HYCROFT MINING HOLDING CORP: Hycroft Mining Holding Corporation is a US-based gold and silver company developing the Hycroft Mine, among the world’s largest precious metals deposits located in northern Nevada , a Tier-One mining jurisdiction. After a long history of oxide heap leaching operations, the Company is focused on completing the technical studies to transition the Hycroft Mine into the next phase of commercial operations for processing the sulfide ore. In addition, the Company is engaged in a robust exploration drill program to further expand the newly discovered high-grade dominant silver systems and unlock the full potential of this world-class asset.
For further information, please contact:info@hycroftmining.comwww.hycroftmining.com | 2026 | 09 / September | | Raw Materials | Business Update | 5 | 1.718.405 | 1.718.405 | HYCROFT MINING HOLDING CORP | Mudrick Capital Acquisition Corp | HYMC | MUDS | HYMC | MUDS | HYMC | Hycroft Provides Project Update and Unveils Refreshed Brand Identity | Hycroft Provides Project Update and Brand Refresh | Hycroft Mining provides a project update on underground development, metallurgical testing, and unveils a refreshed brand identity. | c9482ecf-b603-11f1-aa56-277af14ba041 |
7/10FreeSep 21, 2026 Deep Fission and Youngquist Brothers Partner for Underground Nuclear Reactor Drilling
Fossil Fuel
Strategic Partnership
IPO:
Jun 18, 2026 Industry: ELECTRIC SERVICES Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 21, 2026 11:38 AM ET Deep Fission and Youngquist Brothers Partner for Underground Nuclear Reactor DrillingFort Myers, Fla. - Deep Fission, Inc. (Nasdaq: FISN), an advanced nuclear energy company focused on placing small modular pressurized water reactors approximately one mile underground, has announced a strategic collaboration with Youngquist Brothers, LLC. The partnership aims to evaluate and test advanced drilling and borehole-construction methods for Deep Fission's unique underground reactor deployment model. Under the agreement, both companies will work together to develop large-diameter, deep boreholes utilizing Youngquist's extensive drilling expertise. Recently, the partners successfully completed an equipment demonstration in Fort Myers, Florida, where Deep Fission lowered and retrieved a 30-inch full-size prototype reactor canister into a 34-inch borehole at a depth of approximately 100 feet. This test validated crucial installation and retrieval mechanics.
Youngquist Brothers brings decades of experience in large-diameter drilling, having reached depths exceeding 8,000 feet since 1971. This collaboration allows Deep Fission to leverage established commercial drilling techniques and existing field equipment rather than building infrastructure from scratch. About DEEP FISSION, INC.: We and the underwriters have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or any amendment or supplement to this prospectus. We and the underwriters take no responsibility for, and cannot assure you as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of our common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. | 2026 | 09 / September | | Fossil Fuel | Strategic Partnership | 7 | 1.918.102 | DEEP FISSION, INC. | FISN | FISN | FISN | Deep Fission and Youngquist Brothers Partner for Underground Nuclear Reactor Drilling | Deep Fission & Youngquist Brothers Partner on Borehole Drilling | Deep Fission teams up with Youngquist Brothers to test and evaluate deep, large-diameter borehole drilling for underground nuclear reactor deployment. | 95987f60-b5d1-11f1-aa56-277af14ba041 | ||||
7/10FreeSep 21, 2026 Evolution Metals & Technologies Joins Russell 3000 and Russell 2000 Indexes
Raw Materials
Business Update
Merger:
Jan 06, 2026 Industry: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES Market Cap.: 43.81 m. Show chart?Load external content from TradingView. Enabling this loads external TradingView content. You can change or withdraw your consent at any time under “Optional Services”. Sep 21, 2026 8:45 AM ET Evolution Metals & Technologies Joins Russell 3000 and Russell 2000 IndexesMiami, FL, USA - Evolution Metals & Technologies Corp. (Nasdaq: EMAT), a producer of rare earth permanent magnets and battery materials, has announced its inclusion in both the broad-market Russell 3000 Index and the small-cap Russell 2000 Index. The addition became effective at the opening of U.S. equity markets following FTSE Russell's third-quarter quarterly IPO additions process. Membership in the Russell 2000 Index provides automatic inclusion in the Russell 3000 Index, exposing the company to a significant pool of institutional and benchmarked assets. Company leadership highlighted that this milestone reflects rapid operational execution since its Nasdaq listing, including advancing its Pohang infrastructure expansion to scale annual magnet production to 10,000 metric tons and establishing initial revenue guidance for fiscal 2027. Commercial Expansion in South KoreaThe index addition coincides with the ongoing commercial expansion of the company's rare earth permanent magnet platform in Pohang, Republic of Korea. Backed by a 750-megawatt electrical infrastructure agreement with KEPCO and upcoming deliveries of sintered magnet production machinery, the company is scaling its manufacturing capacity to meet growing demand.
Key Highlights About Evolution Metals & Technologies Corp.: Evolution Metals & Technologies Corp. (Nasdaq: EMAT) is a U.S.-based critical materials and advanced manufacturing company for rare earth permanent magnets, battery materials, and related critical minerals and technologies. By leveraging proven commercial-scale operations, advanced processing technologies, and strategic partnerships, EM&T operates what it believes is the only vertically integrated critical materials supply chain spanning end-of-life electronics and batteries, high-grade concentrates, and the manufacture of finished rare earth magnets (including high-performance rare earth magnets) and battery materials. For additional information, please visit https://investors.evolution-metals.com and follow the Company on LinkedIn at https://www.linkedin.com/company/evolutionmtcorp. | 2026 | 09 / September | | Raw Materials | Business Update | 7 | 1.866.226 | 1.866.226 | Evolution Metals & Technologies Corp. | Welsbach Technology Metals Acquisition Corp. | EMAT | WTMA | EMAT | WTMA | EMAT | Evolution Metals & Technologies Joins Russell 3000 and Russell 2000 Indexes | Evolution Metals Joins Russell 3000 and Russell 2000 | Evolution Metals & Technologies Corp. joins the Russell 3000 and Russell 2000 indexes, expanding its exposure to institutional investors. | dc30c706-b5b9-11f1-aa56-277af14ba041 |